$LH

Kyle Kathryn W sold $26K of LH

Kyle Kathryn W (EVP, Chief Legal Officer) sold 92 shares of LABCORP HOLDINGS INC. (LH) at $286.19 on 2026-07-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Kyle Kathryn W
Published Jul 6, 2026, 1:37 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 6, 2026, 1:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LH
Neutral
high confidence
Mentioned
$LH
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LHNeutralLow
01

Why it matters

Because the sale is explicitly under a pre-arranged Rule 10b5-1 plan, it typically reflects scheduled liquidity rather than new negative information.

02

Market read

A small, scheduled insider sale is unlikely to drive trading decisions beyond routine monitoring.

03

What to watch

The article provides only one transaction size and does not include prior insider activity frequency, option exercises, or any concurrent buys.

Relevance 2/10Novelty 3/10Timing: Filed July 6, covering a sale executed July 2

Background

The disclosure is an SEC Form 4 insider transaction by Kyle Kathryn W (EVP, Chief Legal Officer) for LABCORP HOLDINGS INC.

Company-level read

Ticker impact

$LHNeutralHigh confidence
Context

Form 4 shows LH’s EVP & Chief Legal Officer sold 92 shares at $286.19 on a 10b5-1 plan, totaling $26,329.48.

Expected impact

Minimal near-term impact; any effect is likely sentiment-only and short-lived.

Evidence & confidence

The filing is an open-market sale by an insider with an explicitly stated 10b5-1 plan and small share count/value relative to typical market moves.

Market effects

No clear sector read-through from a single, small 10b5-1 insider sale.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can coincide with internal caution; traders may still monitor for a pattern.

Key entities

  • LABCORP HOLDINGS INC.

    Subject of the Form 4 insider transaction disclosure.

  • Kyle Kathryn W

    EVP, Chief Legal Officer who executed the open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LHMedAI 9/10

Labcorp’s (NYSE:LH) Q3 2026 sales beat estimates

Labcorp reported Q3 2026 revenue of $3.81B, exceeding estimates by 1.2% and growing 6.9% YoY. Adjusted EPS was $4.78, a 2.9% beat. The company raised full-year revenue and EPS guidance. Operating margin remained steady at 10.6%, while free cash flow margin improved to 10.8%. Organic revenue grew 5.5% YoY.

$LHHighAI 8/10

Labcorp shares edge up on beating estimates, raising guidance

Labcorp Holdings Inc. (NYSE:LH) reported Q3 earnings of $4.78 per share, beating estimates by $0.13, with revenue of $3.81 billion, up 6.9% YoY. The company raised full-year guidance for revenue growth to 5.9%-6.7% and adjusted EPS to $18.30-$18.70. Shares rose 1.46% in pre-market trading. Labcorp also announced four acquisitions and paid $58.2 million in dividends.

$LHHighAI 9/10

Labcorp Reports Strong 2026 Third Quarter Results; Raises Full Year 2026 Guidance

LABCORP HOLDINGS INC. (LH) filed an SEC Form 8-K — Results of Operations and Financial Condition. FOR IMMEDIATE RELEASE Contact: Nickolo Russo - Investors Racquel White - Media Investor@labcorp.com Media@labcorp.com Labcorp Reports Strong 2026 Third Quarter Results; Raises Full Year 2026 Guidance • Results from operations for third quarter 2026 versus third quarter 2025: ◦ Re